Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) CEO Ryan J. Watts sold 40,000 shares of the company's stock in a transaction on Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares of the company's stock, valued at approximately $6,529,495.83. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Denali Therapeutics Stock Down 0.3 %
Shares of NASDAQ:DNLI traded down $0.09 during midday trading on Tuesday, hitting $26.29. The stock had a trading volume of 391,812 shares, compared to its average volume of 1,091,888. The company has a market cap of $3.75 billion, a P/E ratio of -27.39 and a beta of 1.38. Denali Therapeutics Inc. has a 12 month low of $14.56 and a 12 month high of $32.13. The business's 50-day simple moving average is $26.91 and its 200-day simple moving average is $22.68.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.59) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.09. The firm had revenue of $1.00 million during the quarter, compared to the consensus estimate of $10.00 million. The business's revenue was down 99.7% on a year-over-year basis. During the same period last year, the business earned $1.30 EPS. As a group, equities analysts predict that Denali Therapeutics Inc. will post -2.54 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on DNLI shares. Raymond James reaffirmed a "market perform" rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Wedbush cut their price target on Denali Therapeutics from $30.00 to $26.00 and set an "outperform" rating on the stock in a report on Friday, August 2nd. JPMorgan Chase & Co. reduced their price objective on Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating for the company in a research report on Friday, October 11th. Citigroup lifted their target price on Denali Therapeutics from $26.00 to $32.00 and gave the company a "buy" rating in a research report on Friday, August 2nd. Finally, HC Wainwright reissued a "buy" rating and issued a $90.00 price objective on shares of Denali Therapeutics in a research report on Wednesday, September 4th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $38.22.
Check Out Our Latest Research Report on DNLI
Institutional Trading of Denali Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Denali Therapeutics by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 10,968,293 shares of the company's stock valued at $225,069,000 after acquiring an additional 133,810 shares during the period. Capital Research Global Investors grew its position in shares of Denali Therapeutics by 107.9% in the first quarter. Capital Research Global Investors now owns 6,049,957 shares of the company's stock valued at $124,145,000 after purchasing an additional 3,140,429 shares during the last quarter. Baker BROS. Advisors LP increased its stake in shares of Denali Therapeutics by 43.1% during the first quarter. Baker BROS. Advisors LP now owns 3,731,695 shares of the company's stock worth $76,574,000 after purchasing an additional 1,124,499 shares during the period. Marshall Wace LLP increased its stake in shares of Denali Therapeutics by 12.7% during the second quarter. Marshall Wace LLP now owns 2,418,833 shares of the company's stock worth $56,165,000 after purchasing an additional 272,454 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Denali Therapeutics by 6.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company's stock worth $32,913,000 after purchasing an additional 84,522 shares during the last quarter. Institutional investors own 92.92% of the company's stock.
Denali Therapeutics Company Profile
(
Get Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Featured Stories
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
